share_log
Benzinga ·  Aug 13 07:40
Cybin Completes FDA Type B Initial Breakthrough Therapy Meeting; Plans For CYB003 Phase 3 Program In Major Depressive Disorder, Expects To Initiate Phase 3 In Late Summer
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment